Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.

ABSTRACT: Infection with Cryptosporidium spp. can cause severe diarrhea, leading to long-term adverse impacts and even death in malnourished children and immunocompromised patients. The only FDA-approved drug for treating cryptosporidiosis, nitazoxanide, has limited efficacy in the populations impacted the most by the diarrheal disease, and safe, effective treatment options are urgently needed. Initially identified by a large-scale phenotypic screening campaign, the antimycobacterial therapeutic clofazimine demonstrated great promise in both in vitro and in vivo preclinical models of Cryptosporidium infection. Unfortunately, a phase 2a clinical trial in HIV-infected adults with cryptosporidiosis did not identify any clofazimine treatment effect on Cryptosporidium i

SUBMITTER: Zhang CX 

PROVIDER: S-EPMC8765308 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature